Drug-Induced Interstitial Pneumonia due to Application of FOLFOX as Adjuvant Chemotherapy after Rectal Cancer Surgery: A Case Report and Literature Review.
Drug-induced pneumonia
FOLFOX
Rectal cancer
Steroid therapy
Journal
Case reports in oncology
ISSN: 1662-6575
Titre abrégé: Case Rep Oncol
Pays: Switzerland
ID NLM: 101517601
Informations de publication
Date de publication:
Historique:
received:
17
04
2020
accepted:
17
04
2020
entrez:
11
8
2020
pubmed:
11
8
2020
medline:
11
8
2020
Statut:
epublish
Résumé
The regimen of oxaliplatin with 5-fluorouracil plus l-leucovorin (FOLFOX) has become one of the most commonly used first-line chemotherapy for patients with advanced colorectal cancer and it provides an increase in disease-free survival as well as an overall survival benefit. Although FOLFOX chemotherapy has helped to improve the clinical outcomes in these patients, the regimen is associated with some therapeutic issues or uncontrolled side effects. Gastrointestinal, neurosensory, and hematological toxicities have frequently been observed in patients treated with FOLFOX, and consequently, some palliative treatment has been established to combat such complications. However, pulmonary toxicities including drug-induced interstitial pneumonia (DI-IP) is rarely observed in these patients and a curative treatment is yet to be established. DI-IP due to chemotherapy is most commonly observed in patients treated with mitomycin, paclitaxel, docetaxel, or gemcitabine. Steroid therapy is mostly used to treat DI-IP, although the efficacy of such treatments is not supported with adequate evidence. FOLFOX-induced interstitial pneumonia (FIIP) is rarely observed, and several case reports of FIIP treated with steroids have been published previously that showed the mortality is extremely high. Here, we present a 74-year-old woman who received modified FOLFOX6 as adjuvant chemotherapy after rectal cancer surgery. The patient experienced FIIP, which improved after application of steroid pulse (high-dose methylprednisolone at 1,000 mg/day for 3 days) and tapering (starting with prednisolone at 40 mg/day) therapy. Our data suggest that such a steroid therapy could represent an effective treatment option for FIIP.
Identifiants
pubmed: 32774274
doi: 10.1159/000507985
pii: cro-0013-0768
pmc: PMC7383214
doi:
Types de publication
Case Reports
Langues
eng
Pagination
768-773Informations de copyright
Copyright © 2020 by S. Karger AG, Basel.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to declare.
Références
Case Rep Oncol Med. 2015;2015:341064
pubmed: 26064729
Arch Bronconeumol. 2015 Nov;51(11):610
pubmed: 26163115
Clin Colorectal Cancer. 2015 Mar;14(1):1-10
pubmed: 25579803
Annu Rev Med. 2015;66:83-95
pubmed: 25341011
Arch Bronconeumol. 2017 Apr;53(4):213-215
pubmed: 27756654
J Oncol Pharm Pract. 2017 Apr;23(3):173-178
pubmed: 26786027
Ann Oncol. 2010 Oct;21(10):2005-2010
pubmed: 20305036
Clin J Gastroenterol. 2011 Jun;4(3):157-161
pubmed: 26189347
Curr Treat Options Oncol. 2018 May 11;19(6):29
pubmed: 29752549
J Clin Med. 2018 Oct 15;7(10):
pubmed: 30326612
Ann Oncol. 2004 Mar;15(3):460-6
pubmed: 14998849
BMC Cancer. 2017 Aug 29;17(1):586
pubmed: 28851379
Case Rep Oncol. 2014 Sep 24;7(3):662-8
pubmed: 25408660
Respir Med. 2008 Feb;102(2):273-9
pubmed: 17945475
Anticancer Res. 2017 Dec;37(12):7037-7042
pubmed: 29187492